1. Home
  2. ATYR vs VSTA Comparison

ATYR vs VSTA Comparison

Compare ATYR & VSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • VSTA
  • Stock Information
  • Founded
  • ATYR 2005
  • VSTA 1966
  • Country
  • ATYR United States
  • VSTA Brazil
  • Employees
  • ATYR N/A
  • VSTA N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • VSTA Other Consumer Services
  • Sector
  • ATYR Health Care
  • VSTA Real Estate
  • Exchange
  • ATYR Nasdaq
  • VSTA Nasdaq
  • Market Cap
  • ATYR 306.2M
  • VSTA 357.6M
  • IPO Year
  • ATYR 2015
  • VSTA 2020
  • Fundamental
  • Price
  • ATYR $4.73
  • VSTA $4.09
  • Analyst Decision
  • ATYR Strong Buy
  • VSTA Sell
  • Analyst Count
  • ATYR 6
  • VSTA 2
  • Target Price
  • ATYR $18.60
  • VSTA $3.00
  • AVG Volume (30 Days)
  • ATYR 1.5M
  • VSTA 52.6K
  • Earning Date
  • ATYR 05-07-2025
  • VSTA 05-08-2025
  • Dividend Yield
  • ATYR N/A
  • VSTA N/A
  • EPS Growth
  • ATYR N/A
  • VSTA N/A
  • EPS
  • ATYR N/A
  • VSTA 1.00
  • Revenue
  • ATYR N/A
  • VSTA $286,712,653.00
  • Revenue This Year
  • ATYR $1,264.26
  • VSTA $13.97
  • Revenue Next Year
  • ATYR $1,239.11
  • VSTA $11.79
  • P/E Ratio
  • ATYR N/A
  • VSTA $4.18
  • Revenue Growth
  • ATYR N/A
  • VSTA 6.46
  • 52 Week Low
  • ATYR $1.42
  • VSTA $1.60
  • 52 Week High
  • ATYR $4.66
  • VSTA $5.49
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 77.04
  • VSTA 45.75
  • Support Level
  • ATYR $4.16
  • VSTA $3.90
  • Resistance Level
  • ATYR $3.94
  • VSTA $4.28
  • Average True Range (ATR)
  • ATYR 0.30
  • VSTA 0.19
  • MACD
  • ATYR 0.13
  • VSTA 0.01
  • Stochastic Oscillator
  • ATYR 96.94
  • VSTA 67.97

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About VSTA Vasta Platform Limited

Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.

Share on Social Networks: